Pfizer (NYSE:PFE) draws attention as raised revenue guidance, non-COVID strength, and an expanding obesity program frame its ...

Pfizer (NYSE:PFE) draws attention as low-multiple pharmaceutical names feature in value-oriented conversations during a ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Explore the exciting world of Pfizer (NYSE: PFE) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...

Pfizer (NYSE: PFE) was founded in 1849. That makes the company well over 100 years old. Not many companies have managed to survive as long as Pfizer has, especially in an industry as highly technical ...

Pfizer's non-COVID-19 portfolio demonstrates resilience, with Padcev, Vyndamax, and new launches driving operational growth ...

Late in 2023 I believed that the potential was still there in the case of Pfizer (PFE) after another setback in the pipeline. To see where Pfizer comes from, we really have to create some perspective, ...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...

Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management reaffirmed expectations for 2025 revenue of $61 billion-$64 billion and ...

Pfizer's stock has fallen more than 50% from its 2021 high. The stock is trading below its pre-coronavirus pandemic level. Pfizer is dealing with what are, in reality, just normal headwinds in the ...